ALK-Abello gains on allergy data

ALK-Abello A/S (CSE:ALK-B) gained DKK20.50 to DKK383.50 on Tuesday after its grass Allergy Immunotherapy Tablet (AIT) met the primary endpoint in a Phase III trial to treat grass pollen-induced allerg...